Maintaining weight loss in obesity goes beyond GLP-1s: ‘The hard work is just beginning’

Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy.The FDA approval of obesity drugs including semaglutide (Wegovy/Wegovy pill, Novo Nordisk), tirzepatide (Zepbound, Eli Lilly) and orforglipron (Foundayo, Eli Lilly) led to a surge in their use. However, health care professionals continue to emphasize the importance of